N- ((4'- hydroxybiphenyl- 3- yl)methyl)- 2- (3- (2- ((- 2- hydroxy- 2- (4- hydroxy- 3- ((methylsulfonyl)amino)phenyl)ethyl)amino)- 2- methylpropyl)phenyl)acetamide

11/01/2013 - "This PKPD analysis supports the clinical observation that no relevant effects of PF-00610355 on heart rate in COPD patients should be expected for doses up to 280 μg once daily."
11/01/2013 - "Simulations suggested a maximum placebo-corrected increase of 2.7 (0.90-4.82) beats min(-1) in COPD patients for a PF-00610355 dose of 280 μg once daily, with 19% subjects experiencing a heart rate increase of more than 20 beats min(-1) compared with 8% in the placebo group. "
11/01/2013 - "The median heart rate increase in COPD patients for doses of PF-00610355 up to 280 μg once daily was simulated with the final pharmacokinetic/pharmacodynamic (PKPD) model. "
06/01/2013 - "The estimated systemic pre-dose and maximum PF-00610355 plasma concentration was 23 and 38 % in COPD patients compared to healthy volunteers, respectively. "
06/01/2013 - "Model-based mean (95 % CI) exposure profiles for a range of PF-00610355 doses in COPD patients were simulated. "

06/01/2013 - "A total of 6,107 samples of PF-00610355 plasma concentration, collected in 264 subjects from eight studies in healthy volunteers, asthma, and COPD patients, were analyzed using non-linear mixed-effects models. "